Quantitation of 22 fentanyl analog compounds with a TSQ Altis MD mass spectrometer

Significance of the Topic

The rapid emergence of novel fentanyl analogs has intensified the opioid crisis and created an urgent demand for analytical methods capable of quantifying these compounds at low concentrations in biological matrices. Accurate measurement of a broad panel of synthetic opioids in urine supports clinical research, forensic toxicology, and public health monitoring.

Study Objectives and Overview

This study aimed to demonstrate the speed, sensitivity, and reproducibility of the Thermo Scientific™ TSQ Altis™ MD triple quadrupole mass spectrometer coupled with the Vanquish™ MD UHPLC system for quantifying 22 fentanyl analogs in urine. The method employs a Traceable Opioid Material™ kit with matched isotopically labeled internal standards to ensure confident identification and quantitation.

Methodology

A 13-point calibration curve (0.01–100 ng/mL) and quality control samples (1.0, 2.5, and 25 ng/mL) were prepared in human urine. Sample cleanup utilized supported liquid extraction (SLE) on Biotage ISOLUTE SLE+ 400 plates, followed by evaporation and reconstitution in water:methanol (90:10, v/v). Chromatographic separation was achieved on an Accucore Phenyl Hexyl column (2.1 × 100 mm, 2.6 µm) at 40 °C using a 7.5-minute gradient with mobile phases of 2 mM ammonium formate/0.1% formic acid in water (A) and in methanol:acetonitrile (50:50, B). A 10 µL injection volume was used.
Mass spectrometric detection was performed in positive electrospray ionization mode with an OptaMax™ NG source on the TSQ Altis MD. Selected reaction monitoring (SRM) employed three transitions per analyte (one quantifier, two qualifiers) at 0.7 Da resolution and a 0.7 s cycle time. Calibration employed 1/x² weighting with the origin ignored.

Instrumentation Used

• Thermo Scientific Vanquish MD UHPLC system with high-pressure gradient pump and autosampler
• Thermo Scientific Accucore Phenyl Hexyl column (2.1 × 100 mm, 2.6 µm) at 40 °C
• Thermo Scientific TSQ Altis MD triple quadrupole mass spectrometer with OptaMax NG electrospray source
• Biotage ISOLUTE SLE+ 400 plates for supported liquid extraction
• TraceFinder LDT 1.0 software for data processing and calibration

Major Results and Discussion

All 22 fentanyl analogs eluted between 1.5 and 4 minutes with clear separation in a 7.5-minute run. Limits of quantitation (LOQs) met criteria of ±20% bias and <20% CV. The TSQ Altis MD achieved LOQs ≤0.25 ng/mL for 20 of the compounds, and two compounds reached 0.05 ng/mL sensitivity. Linear dynamic ranges extended to 100 ng/mL with R² > 0.99 for all analytes. Representative SRM chromatograms at the LOQ for benzyl fentanyl (0.1 ng/mL) and valeryl fentanyl (5 ng/mL) confirmed robust detection and reproducibility.

Practical Benefits and Applications

• High throughput with a 7.5-minute analysis time per sample
• Sub-ng/mL sensitivity across a broad panel of fentanyl analogs
• Accurate quantitation in urine using matched isotopically labeled internal standards
• Applicable to clinical research, forensic toxicology, and regulatory monitoring

Future Trends and Potential Applications

Continued advancement may include integration with high-resolution mass spectrometry for untargeted screening, automation of sample preparation workflows, expansion to emerging synthetic opioids, and adaptation for point-of-care diagnostics or large-scale epidemiological studies.

Conclusions

The described UHPLC-SRM method on the Vanquish MD and TSQ Altis MD offers a rapid, sensitive, and reproducible approach for quantifying 22 fentanyl analogs in urine. The combination of supported liquid extraction, isotopic calibration, and optimized SRM provides a robust analytical platform to address the growing need for comprehensive synthetic opioid analysis.

References

1. Centers for Disease Control and Prevention. Death Rate Maps & Graphs; 2021 data on synthetic opioid overdose deaths.
2. Wilson N, et al. Drug and Opioid-Involved Overdose Deaths – United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290–297.
3. Cerilliant Corporation. Opioid Certified Reference Material Kit; collaboration with CDC for fentanyl analog standards.
4. Cayman Chemical. Fentanyl Analog Screening Kit and Emergent Panels.